TICKERNERD
Menu
CRDLCRDLHealthcare · Drug Manufacturers - Specialty & Generic

CRDL Stock Forecast: Cardiol Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.00
+0.76% on the day

The 6 Wall Street analysts covering Cardiol Therapeutics, Inc. hold a median 12-month price target of $9.03 — +352.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$233.1M
Ticker Nerd rank
61 / 100
Median analyst target
$9.03
Analysts covering
6
Revenue$0.0
Operating income−$7.9M
Net income−$6.1M
Free cash flow−$4.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.6%
1M
+33.0%
YTD
+109.1%
1Y
+86.4%
From 52W high
−12.7%
From 52W low
+115.4%
$0.93
$2.29
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRDL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cardiol Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
61 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
77
Momentum
76
Growth
68
Size
66
Revisions
63
Value
57
Accruals
53
Issuance
36
Quality
16

Volatility (77): The share price has been relatively steady.

Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRDL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRDL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26CRDLHigh $11.01Median $9.03Low $4.95

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $4.95Median $9.03High $11.01

The green dot is the last close — the median target sits +352.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026Canaccord GenuityMaintainsBuy$8.00 → $10
14 July 2026HC Wainwright & Co.ReiteratesBuy$9.00
14 July 2026HC Wainwright & Co.ReiteratesBuy—
6 Apr 2026Canaccord GenuityMaintainsBuy—
6 Apr 2026Canaccord GenuityMaintainsBuy$8.00
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
1 Dec 2025HC Wainwright & Co.ReiteratesBuy—
2 June 2025HC Wainwright & Co.InitiatesBuy—
16 Apr 2025HC Wainwright & Co.ReiteratesBuy—
7 Apr 2025HC Wainwright & Co.ReiteratesBuy—
24 Feb 2025HC Wainwright & Co.ReiteratesBuy—
18 Dec 2024HC Wainwright & Co.ReiteratesBuy—
20 Nov 2024HC Wainwright & Co.ReiteratesBuy—
24 Oct 2024HC Wainwright & Co.ReiteratesBuy—
26 June 2024Roth MKMInitiatesBuy—
14 June 2024HC Wainwright & Co.ReiteratesBuy—
7 June 2024HC Wainwright & Co.ReiteratesBuy—
23 May 2024Canaccord GenuityMaintainsBuy—
14 May 2024HC Wainwright & Co.ReiteratesBuy—
22 Apr 2024HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRDL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CRDL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Cardiol Therapeutics, Inc. returned +86.4% against +17.5% for the S&P 500, dividends included.

CRDL vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Oct 25Jan 26Apr 26Jul 26CRDLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CRDL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Cardiol Therapeutics, Inc. (CRDL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.1×

Cheaper than 90% of US stocks

Price / sales
—
Price / book
13.3×

Cheaper than 7% of US stocks

EV / EBITDA
−5.8×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−190.2%

Higher than 8% of US stocks

Return on assets
−90.9%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cardiol Therapeutics, Inc. (CRDL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cardiol Therapeutics, Inc. has a market value of $233.1M and an enterprise value of $149.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$34.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$24.1M.

  • Shares outstanding: 115.3M.

  • Trailing P/E: −5.1×; forward P/E: −8.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Cardiol Therapeutics, Inc. employs 18 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

CRDL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
CRDLCardiol Therapeutics, Inc.$233.1M
61
ACBAurora Cannabis, Inc.$242.2M
48
SIGASIGA Technologies, Inc.$217.1M
41
AKBAAkebia Therapeutics, Inc.$254.9M
78
DERMJourney Medical Corp.$197.6M
65
ANIKAnika Therapeutics, Inc.$279.5M
100
ORGOOrganogenesis Holdings, Inc.$189.1M
50

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cardiol Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRDL news & analysis

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

PRNewsWire · 10 Sept 2026neutral

Cardiol Therapeutics announced it has filed a preliminary short form base shelf prospectus with Canadian securities regulators, along with a corresponding registration statement on Form F-10 with the SEC, for a proposed US$150 million base shelf offering under the U.S./Canada Multijurisdictional Disclosure System.

Why it matters — The shelf prospectus filing gives Cardiol the regulatory framework to potentially raise up to US$150 million in future capital, which is relevant for investors tracking the company's financing capacity.

Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

PRNewsWire · 9 Sept 2026neutral

Cardiol Therapeutics announced it will participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference. The company, which develops anti-inflammatory and anti-fibrotic therapies for heart disease, made the announcement on September 9, 2026.

Why it matters — The conference appearance gives Cardiol Therapeutics a platform to present its late-stage heart disease therapies to investors and industry participants.

Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research · 25 Aug 2026neutral

Zacks Investment Research compares the year-to-date performance of Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) against their medical sector. The article examines how each stock has fared relative to its peers so far this year.

Why it matters — CRDL watchers would care because the piece assesses how the company's stock is tracking relative to its medical-sector peers over the current year.

Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?

Zacks Investment Research · 24 Aug 2026positive

Zacks Investment Research has published an article examining whether Cardiol Therapeutics Inc. (CRDL) could qualify as a top momentum stock pick for investors. The piece poses the question of whether CRDL's momentum makes it a worthwhile pick, without providing definitive conclusions in the excerpt.

Why it matters — A CRDL watcher would care because this analysis focuses on the company's market momentum, a factor that can influence investor attention and stock performance.

Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial

MarketBeat · 12 Aug 2026positive

Cardiol Therapeutics is advancing its synthetic cannabidiol formulation, CardiolRx, in a pivotal Phase III trial for recurrent pericarditis, with management viewing the program as a key step toward a potential new drug application.

Why it matters — Progress in this Phase III trial brings CardiolRx closer to a potential FDA submission, making it a critical milestone for the company's pipeline and future regulatory pathway.

FAQ

Frequently asked questions about CRDL stock

What is the CRDL stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Cardiol Therapeutics, Inc. have a median 12-month price target of $9.03, with estimates ranging from $4.95 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRDL stock a buy right now?

Of the 6 analysts covering Cardiol Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cardiol Therapeutics, Inc. 61 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRDL?

As at 12 Sept 2026, Cardiol Therapeutics, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (77 of 100).

Will CRDL stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +352.6% from the last close, and Ticker Nerd's factor model ranks Cardiol Therapeutics, Inc. 61 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRDL stock forecast for 2030?

No analyst covering Cardiol Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRDL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.95 to $11 over the next 12 months.

How has CRDL stock performed over the past year?

Cardiol Therapeutics, Inc. returned +86.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cardiol Therapeutics, Inc. do?

Cardiol Therapeutics Inc. Class A Common Shares represents an equity interest in Cardiol Therapeutics, a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease.

What is the latest news on CRDL?

The most recent item we track (PRNewsWire, 10 Sept 2026): "Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission". Cardiol Therapeutics announced it has filed a preliminary short form base shelf prospectus with Canadian securities regulators, along with a corresponding registration statement on Form F-10 with the SEC, for a proposed US$150 million base shelf offering under the U.S./Canada Multijurisdictional Disclosure System.

Company

About Cardiol Therapeutics, Inc.

Cardiol Therapeutics Inc. Class A Common Shares represents an equity interest in Cardiol Therapeutics, a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. The company’s current work centers on CardiolRx, a pharmaceutically manufactured oral cannabidiol formulation in clinical development for cardiovascular indications, including inflammatory heart conditions. Cardiol Therapeutics also advances related formulations and programs aimed at addressing the biological pathways involved in cardiac inflammation and fibrosis. Its business is concentrated in the biotechnology and pharmaceutical segments of the healthcare market, where it contributes to the development of specialized therapies for serious heart disorders. Based in Oakville, Ontario, Cardiol Therapeutics is positioned as a research-driven company with a narrow therapeutic focus on heart disease treatment.

CEO Mr. David G. Elsley MBA · 18 employees · Canada · https://www.cardiolrx.com